Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Krystal Biotech Inc

KRYS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$332.27

▲ +1.20%

Market Cap $9.83B · Vol 69.33K

Key Metrics

P/E Ratio

41.66

FWD: 38.48

Market Cap

$9.83B

Mid Cap

Div Yield

N/A

EPS Growth

+11.88%

YoY

RSI (14)

41.52

Momentum

Beta

0.52

vs Market

52W High

$382.26

13.08% below

52W Low

$136.88

142.75% above

Volume

69.33K

Avg 181.90K

P/B

5.90

Price-to-book

ROE

18.91%

Return on equity

Free Float

87.22%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Krystal Biotech Inc (KRYS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KRYS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.78%

-2.11%

+5.05%

+20.19%

YTD

+34.77%

+121.03%

+172.44%

+491.44%

Financials & Valuation

TTM · Annual

Total Revenue	$389.13M
Net Income	$204.83M
Revenue Growth (YoY)	+24.14%
Gross Margin	94.08%
Operating Margin	41.45%
Net Profit Margin	52.64%
ROE	18.91%
ROA · ROIC	15.86% · 18.91%

P/E Ratio	41.66
Forward P/E (FY1)	38.48
PEG Ratio	0.28
P/S	18.98
P/B	5.90
P/FCF	39.09
EPS Growth	+11.88%
Outstanding Shares	29.60M

Technical Indicators

50-Day SMA	$342.10
200-Day SMA	$278.81
RSI (14)	41.52
Beta	0.52
52-Week High	$382.26
52-Week Low	$136.88

Volume Today	69.33K
Avg Daily Volume (30D)	181.90K
Relative Volume	0.38x
Volatility (10D)	50.85
Volatility (30D)	50.75
Free Float	87.22%

Analyst Consensus

BUY

Current Price $332.27

Mean Target $366.76

52W Low$136.88 52W High$382.26

Current

Target

$136.88 $382.26

Current Analyst target

+10.38% upside potential · 13 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00HDGRHJ5

ISINUS5011471027

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.